Innogenetics acquires therapeutic vaccine program of Genencor
Innogenetics strengthens therapeutic vaccine pipeline in the fields of hepatitis B, human papillomavirus, and hepatitis C
30-Mar-2004 -
Gent (Belgium). Innogenetics announced that it has acquired the therapeutic vaccine programs of US-based Genencor International, Inc.. Innogenetics will be responsible for the clinical development and worldwide commercialization of all products arising from these programs. Through this deal, ...
Belgium
clinical trials
hepatitis C
+5